Compare DX & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DX | SUPN |
|---|---|---|
| Founded | 1987 | 2005 |
| Country | United States | United States |
| Employees | 28 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.8B |
| IPO Year | N/A | 2010 |
| Metric | DX | SUPN |
|---|---|---|
| Price | $13.25 | $46.97 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $14.75 | ★ $61.60 |
| AVG Volume (30 Days) | ★ 5.3M | 916.2K |
| Earning Date | 04-20-2026 | 05-05-2026 |
| Dividend Yield | ★ 15.11% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $392,755,000.00 |
| Revenue This Year | N/A | $22.70 |
| Revenue Next Year | N/A | $19.14 |
| P/E Ratio | $5.66 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.83 | $32.21 |
| 52 Week High | $14.93 | $59.68 |
| Indicator | DX | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 56.26 | 50.30 |
| Support Level | $13.15 | $43.43 |
| Resistance Level | $14.09 | $52.36 |
| Average True Range (ATR) | 0.20 | 1.65 |
| MACD | 0.01 | 0.21 |
| Stochastic Oscillator | 75.00 | 39.86 |
Dynex Capital Inc is a real estate investment trust (REIT) focused on delivering dividends supported by long term returns from investments in mortgage assets backed by U.S. housing and commercial real estate. The Company is internally managed and mainly invests in residential and commercial mortgage-backed securities (RMBS and CMBS), which are Agency securities guaranteed by U.S. government-sponsored enterprises (GSEs). It manages interest rate, prepayment, spread, liquidity, and counterparty risks and operates through one reportable segment investing in MBS funded with repurchase agreements and equity.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.